|
Age, years (Median, IQR)
|
13.6 (11.4, 15.4)
|
13.1 (11.4, 15.3)
|
13.9 (11.4, 15.4)
|
|
Sex, male
|
29 (63.04%)
|
13 (56.52%)
|
16 (69.57%)
|
|
Race, white
|
30 (71.43%) [N = 42]
|
16 (72.73%) [N = 22]
|
14 (70.00%) [N = 20]
|
|
HLA-B27 positive
|
23 (50.00%)
|
14 (60.87%)
|
9 (39.13%)
|
|
Hip arthritis
|
12 (26.09%)
|
8 (34.78%)
|
4 (17.39%)
|
|
Lower back pain
|
27 (58.70%)
|
12 (52.17%)
|
15 (65.22%)
|
|
Morning stiffness (> 15 min)
|
20 (45.45%) [N = 44]
|
10 (45.45%) [N = 22]
|
10 (45.45%) [N = 22]
|
|
Disease duration, months (Median, IQR)
|
11.3 (3.7, 23.7)
|
9.5 (2.9, 20.3)
|
12.0 (3.9, 36.2)
|
|
Active peripheral joint count (Median, IQR)
|
0.0 (0.0, 2.0)
|
0.0 (0.0, 2.0)
|
0.0 (0.0, 2.0)
|
|
Tender entheses (Median, IQR)
|
1.5 (0.0, 4.0)
|
0.0 (0.0, 5.0)
|
2.0 (0.0, 4.0)
|
|
Physician global (0–10; Median, IQR)
|
2.0 (2.0, 4.0) [N = 34]
|
2.0 (2.0, 4.0) [N = 21]
|
2.0 (1.0, 3.0) [N = 13]
|
|
Patient global (0–10; Median, IQR)
|
4.3 (2.0, 6.0) [N = 30]
|
5.0 (3.0, 6.0) [N = 19]
|
2.0 (1.0, 7.0) [N = 11]
|
|
Patient pain (0–10; Median, IQR)
|
5.0 (1.6, 7.0) [N = 30]
|
5.6 (2.0, 7.0) [N = 19]
|
3.0 (1.0, 7.0) [N = 11]
|
|
csDMARD use during follow-up
|
17 (36.96%)
|
8 (34.78%)
|
9 (39.13%)
|
|
Non-TNFi bDMARD use during follow-up*
|
4 (8.70%)
|
4 (17.39%)
|
0 (0.00%)
|
|
NSAID use during follow-up
|
32 (69.57%)
|
12 (52.17%)
|
20 (86.96%)
|
